Antitumor effect of recombinant mouse interleukin-33 in mice

JIANG Liya; LUO Ping; DENG Shaorong; YE Hao; YU Yan; HAN Wei

doi:10.11665/j.issn.1000-5048.20200510

Journal of China Pharmaceutical University > 2020 > 51(5): 584-590. > DOI: 10.11665/j.issn.1000-5048.20200510

JIANG Liya, LUO Ping, DENG Shaorong, YE Hao, YU Yan, HAN Wei. Antitumor effect of recombinant mouse interleukin-33 in mice[J]. Journal of China Pharmaceutical University, 2020, 51(5): 584-590. DOI: 10.11665/j.issn.1000-5048.20200510

Citation:

PDF (635 KB)

Antitumor effect of recombinant mouse interleukin-33 in mice

Funds: This study was supported by the National Natural Science Foundation of China (No.81673446/H3105)

More Information

Received Date: November 17, 2019
Revised Date: September 21, 2020

Graphical Abstract

Abstract

Abstract

To explore the effect of IL-33 on various tumor types,exogenous injection of recombinant mouse IL-33 protein (mIL-33) was used to study the efficacy of different subcutaneous tumor-bearing mouse models. In this study,mIL-33 has been found to significantly inhibit the growth of liver,lung,gastric,prostate,and colon cancers. However,the inhibition of tumor growth by mIL-33 was not completely consistent in different types of tumor. A lower dose of mIL-33 (10 μg/kg) significantly inhibited tumor growth in subcutaneous tumor-bearing mice of liver,lung,and gastric cancers,while a higher dose of mIL-33 (90 μg/kg) was required to exert the corresponding antitumor effect in subcutaneous tumor-bearing mouse models with prostate and colon cancers. In addition,the growth inhibitory effect of mIL-33 on subcutaneous tumors of colon cancer was also correlated with the duration of administration and the stage of tumor progression. The results of this study indicate that mIL-33 significantly inhibits the growth of a variety of tumors,suggesting that IL-33 might be an effective target for tumor treatment.
- mIL-33,
- antitumor,
- liver cancer,
- lung cancer,
- prostate cancer,
- colon cancer

FullText(HTML)

References (23)

References

[1]	. Immunol Rev，2018，281（1）：154?168.
[2]	de la Fuente M，MacDonald TT，Hermoso MA. The IL-33/ST2 axis：role in health and disease［J］. Cytokine Growth Factor Rev，2015，26（6）：615?623.
[3]	Yang Y，Wang JB，Li YM，et al. Role of IL-33 expression in oncogenesis and development of human hepatocellular carcinoma［J］. Oncol Lett，2016，12（1）：429?436.
[4]	Zhang P，Liu XK，Chu Z，et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications［J］. J Int Med Res，2012，40（5）：1654?1661.
[5]	Jin ZQ，Lei L，Lin DD，et al. IL-33 released in the liver inhibits tumor growth via promotion of CD4⁺ and CD8⁺ T cell responses in hepatocellular carcinoma［J］. J Immunol，2018，201（12）：3770?3779.
[6]	Deng X，Xiong YQ，Ma B，et al. Expression of interleukin-33 in non-small cell lung cancer patients and its clinical significance［J］. Chin J Exp Surg（中华实验外科杂志），2016，33（4）：1122?1125.
[7]	Gao K，Li XY，Zhang L，et al. Transgenic expression of IL-33 activates CD8⁺ T cells and NK cells and inhibits tumor growth and metastasis in mice［J］. Cancer Lett，2013，335（2）：463?471.
[8]	Deng KY，Wang H，Shan T，et al. Tristetraprolin inhibits gastric cancer progression through suppression of IL-33［J］. Sci Rep，2016，6：24505.
[9]	Eissmann MF，Dijkstra C，Jarnicki A，et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization［J］. Nat Commun，2019，10（1）：2735.
[10]	Saranchova I，Han J，Huang H，et al. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker interleukin-33［J］. Sci Rep，2016，6：30555.
[11]	Zhou YX，Ji Y，Wang HG，et al. IL-33 promotes the development of colorectal cancer through inducing tumor-infiltrating ST2L⁺ regulatory T cells in mice［J］. Technol Cancer Res Treat，2018，17：1533033818780091.
[12]	Zhang Y，Davis C，Shah S，et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis［J］. Mol Carcinog，2017，56（1）：272?287.
[13]	Xia YL，Ohno T，Nishii N，et al. Endogenous IL-33 exerts CD8⁺ T cell antitumor responses overcoming pro-tumor effects by regulatory T cells in a colon carcinoma model［J］. Biochem Biophys Res Commun，2019，518（2）：331?336.
[14]	O''''Donnell C，Mahmoud A，Keane J，et al. An antitumorigenic role for the IL-33 receptor，ST2L，in colon cancer［J］. Br J Cancer，2016，114（1）：37?43.
[15]	Eissmann MF，Dijkstra C，Wouters MA，et al. Interleukin 33 signaling restrains sporadic colon cancer in an interferon-γ-dependent manner［J］. Cancer Immunol Res，2018，6（4）：409?421.
[16]	Luo P，Deng SR，Ye H，et al. The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling［J］. Biomed Pharmacother，2020，127：110232.
[17]	Gao Q，Han Y，Xu W，et al. Combination of a single-chain variable fragment JZC00 with 2-deoxyglucose inhibited tumor growth in murine models［J］. J China Pharm Univ（中国药科大学学报），2020，51（2）：206?212.
[18]	Deng SR，Deng Q，Zhang YJ，et al. Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer［J］. Cancer Lett，2019，443：1?12.
[19]	Wang KL，Shan S，Yang ZJ，et al. IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model［J］. Oncotarget，2017，8（40）：68571?68582.
[20]	Wang CH，Chen ZS，Bu XM，et al. IL-33 signaling fuels outgrowth and metastasis of human lung cancer［J］. Biochem Biophys Res Commun，2016，479（3）：461?468.
[21]	He ZX，Chen LL，Souto FO，et al. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc ^Min/+ mice［J］. Sci Rep，2017，7（1）：5520.
[22]	Lu BF，Yang M，Wang QQ. Interleukin-33 in tumorigenesis，tumor immune evasion，and cancer immunotherapy［J］. J Mol Med，2016，94（5）：535?543.
[23]	Fournié JJ，Poupot M. The pro-tumorigenic IL-33 involved in antitumor immunity：a Yin and Yang cytokine［J］. Front Immunol，2018，9：2506.

Cited By

Get Citation

PDF

XML

Article views (156) PDF downloads (530)

Turn off MathJax

Article Contents

Abstract

References

Antitumor effect of recombinant mouse interleukin-33 in mice

Abstract

References

Catalog

Export File

Citation

Format

Content